Bayer's Xofigo carves out niche

Share this article:
NICE says no to Xofigo, Zaltrap
Bayer's Xofigo carves out niche

Bayer's cancer drug Xofigo is already a revenue driver for manufacturer Bayer. The company announced that the drug, approved for castration-resistant metastatic prostate cancer, earned $57 million during the quarter, and cited the drug as one of the quarter's key sales drivers along with newish blood thinner Xarelto and wet age-related macular degeneration drug Eylea.

Consultancy Decision Resources is also taking note, reporting Wednesday that over two-thirds of surveyed oncologists have prescribed the drug since its May 2013 approval and that a significant chunk of doctors who said they had yet to prescribe the treatment indicated that they expect to by the year's end.

Decision Resources says about a third of prescribing doctors are using the alpha-emitting radiopharmaceutical along with other drugs including Janssen's Zytiga (aberacitone acetate) and AbbVie's Lupron (leuprolide acetate).

Decision Resources Group Analyst Jennifer Bamford said in a statement that the drug is tripping over some basics, such as providers not being familiar with it. She also said doctors find the need for a nuclear medicine facility off-putting.

Bayer's expectations for the drug indicate the company considers these as minor points—the drugmaker estimated last year that the cancer medication could reach $1.31 billion in annual sales.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Channel

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...